MorphoSys granted Novozymes non-exclusive rights to use MorphoSys' Slonomics technology to develop products for industrial biotechnology applications

MorphoSys AG

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Novozymes A/S

Denmark / Other

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced